Levofloxacin

Introduction Overview

Generic Name

levofloxacin

Brand Name

Levaquin

Dosage Form

oral tablet, oral solution

Drug Class

Quinolones and fluoroquinolones

Pharmacokinetics

Absorption:
Levofloxacin is rapidly and almost completely absorbed after oral administration, with peak plasma concentrations occurring approximately 1-2 hours post-dose. The absolute bioavailability of oral levofloxacin approaches 99%, indicating that oral and intravenous administration yield similar systemic exposures. Absorption is not significantly affected by food intake with tablets, although the oral solution should be taken on an empty stomach to optimize absorption. Concomitant administration of multivalent cation-containing products such as antacids, sucralfate, didanosine, or supplements containing aluminum, magnesium, iron, or zinc can impair levofloxacin absorption, requiring dosing separation of at least 2 hours before or after these agents.

Distribution:
Levofloxacin distributes widely throughout body tissues and fluids, achieving concentrations exceeding those in plasma in many tissues such as lung, skin, prostate, and sinuses. The volume of distribution averages approximately 89-112 liters, indicating extensive tissue penetration. Plasma protein binding is modest (~24-38%), primarily to albumin, allowing free drug to exert antimicrobial effects. Levofloxacin crosses the blood–brain barrier to a limited extent but achieves therapeutic concentrations in bronchial mucosa, bronchial secretions, and aqueous humor. Its penetration into macrophages enhances its activity against intracellular pathogens.

Metabolism:
Levofloxacin undergoes minimal hepatic metabolism, with the vast majority of the administered dose excreted unchanged. Less than 5% is metabolized, mainly via oxidation to minor inactive metabolites. Therefore, hepatic impairment has minimal effect on overall clearance. The lack of significant metabolism reduces the potential for drug-drug interactions mediated through cytochrome P450 enzymes.

Elimination:
Levofloxacin is primarily eliminated by renal excretion via glomerular filtration and active tubular secretion. Approximately 85% of the administered dose is recovered unchanged in urine within 48 hours. The plasma elimination half-life ranges from 6 to 8 hours in healthy adults, permitting once-daily dosing. Renal impairment reduces clearance and prolongs half-life, necessitating dosage adjustment in patients with decreased creatinine clearance to prevent drug accumulation and toxicity. Non-renal routes of elimination, such as biliary excretion, are negligible.

Dosage Forms

Available Dosage Forms:
Levofloxacin is available in two primary oral dosage forms:
- Oral tablets: 250 mg, 500 mg, and 750 mg strengths.
- Oral solution: 25 mg/mL concentration (typically supplied as 60 mL bottles).

Dosages for Adults and Adolescents:
Standard adult dosing varies based on infection type and severity. Typical regimens include 250 mg to 750 mg once daily. For example, uncomplicated urinary tract infections may be treated with 250 mg once daily for 3 days, whereas more severe infections like pneumonia or anthrax require 500-750 mg daily for 7 to 14 days. The duration and dose depend on the pathogen, site of infection, and patient factors. Adolescents may receive similar dosing regimens with careful monitoring.

Specific Patient Populations:
- Renal Impairment: Dose adjustments are essential in patients with impaired renal function (creatinine clearance <50 mL/min) to avoid toxicity; dosing intervals may be extended or doses reduced.
- Pediatric Use: Safety and efficacy have not been fully established; use is generally not recommended without specialist consultation due to risk of musculoskeletal adverse effects.
- Elderly Patients: No initial dose adjustment is generally required solely based on age; however, renal function should be assessed due to often decreased clearance.
- Pregnancy and Lactation: Use is generally contraindicated or avoided due to insufficient data and potential risks.

Clinical Guidelines recommend strict adherence to prescribed doses and duration to maximize efficacy and minimize resistance development.

Mechanism Of Action

Levofloxacin belongs to the class of fluoroquinolone antibiotics that exert bactericidal activity by inhibiting essential bacterial enzymes involved in DNA replication. Specifically, it targets bacterial DNA gyrase (topoisomerase II) and topoisomerase IV. These enzymes regulate the supercoiling and untangling of bacterial DNA necessary for replication, transcription, repair, and recombination.

By binding to the enzyme-DNA complex, levofloxacin stabilizes double-stranded DNA breaks generated during the normal functioning of DNA gyrase and topoisomerase IV. This action prevents re-ligation of the DNA strands, leading to accumulation of breaks, interruption of vital processes, and ultimately bacterial cell death. This dual targeting allows activity against a broad spectrum of Gram-positive and Gram-negative bacteria.

Levofloxacin exhibits concentration-dependent killing with a prolonged post-antibiotic effect, meaning bacterial growth remains suppressed even after plasma concentrations fall below the minimum inhibitory concentration (MIC). These properties contribute to its effectiveness with once-daily dosing.

Compared to earlier quinolones, levofloxacin demonstrates enhanced potency against Gram-positive organisms, including Streptococcus pneumoniae, due to greater affinity for topoisomerase IV. Its fluoro substitution at position 6 increases cell penetration and enzyme binding, while modifications at other molecular sites improve pharmacokinetics and safety profile.

Clinical studies have confirmed levofloxacin’s efficacy in treating respiratory tract infections, urinary tract infections, skin infections, and anthrax exposure. Resistance mechanisms primarily include mutations in target enzymes, efflux pumps, and reduced permeability, which necessitates judicious use to prevent development of resistant strains.

Pharmacological Actions

Exerts bactericidal activity through inhibition of bacterial DNA gyrase and topoisomerase IV enzymes.
Displays broad-spectrum antimicrobial activity effective against both Gram-positive and Gram-negative pathogens.
Concentration-dependent killing with a prolonged post-antibiotic effect enhances clinical efficacy.
Penetrates well into respiratory tissues, urinary tract, skin, and prostate enabling treatment of diverse infections.
Has immunomodulatory effects that may reduce bacterial virulence and inflammation.
Minimal metabolism reduces potential for cytochrome P450-mediated drug interactions.
Demonstrates high oral bioavailability, ensuring effective plasma drug levels with oral dosing.
Widely distributed in body tissues, achieving concentrations exceeding MIC of many pathogens.
Exhibits activity against atypical pathogens such as Mycoplasma and Chlamydia species.
Useful in preventing and treating infections following anthrax exposure due to FDA approval.
Overcomes some bacterial resistance due to dual targeting of DNA gyrase and topoisomerase IV.
Effective against multi-drug resistant strains in certain clinical contexts.
Once-daily dosing improves patient compliance and convenience.

Therapeutic Or Clinical Uses

Treatment of community-acquired and nosocomial pneumonia.
Management of acute bacterial sinusitis.
Treatment of complicated and uncomplicated urinary tract infections, including pyelonephritis.
Management of acute bacterial exacerbations of chronic bronchitis.
Treatment of skin and soft tissue infections caused by susceptible bacteria.
Post-exposure prophylaxis and treatment of inhalational anthrax caused by Bacillus anthracis.
Treatment of plague (Yersinia pestis) infections.
Management of prostatitis due to susceptible microorganisms.
Empiric treatment for certain gastrointestinal infections like complicated intra-abdominal infections.
Alternative for treatment of multidrug-resistant bacterial infections when other agents are contraindicated.
Used in certain cases of tuberculosis for multi-drug resistant strains under specialist guidance.
Treatment of infectious diarrhea caused by susceptible strains of Escherichia coli and Shigella.

Side Or Adverse Effects

Tendonitis and tendon rupture, particularly involving the Achilles tendon; risk increased with age, corticosteroid use, and organ transplantation.
Peripheral neuropathy and potential for permanent nerve damage manifesting as numbness, tingling, or burning pain.
Central nervous system effects including headache, dizziness, confusion, agitation, hallucinations, and mood changes.
Hypoglycemia and hyperglycemia; severe cases can lead to coma.
Gastrointestinal disturbances such as nausea, diarrhea, constipation, and abdominal pain.
Photosensitivity reactions causing increased susceptibility to sunburn.
Severe hypersensitivity reactions including anaphylaxis, Stevens-Johnson syndrome, and toxic epidermal necrolysis.
Liver toxicity presenting with jaundice, elevated liver enzymes, and hepatic failure in rare cases.
QT interval prolongation leading to risk of cardiac arrhythmias, especially in patients with pre-existing conditions.
Increased intracranial pressure manifesting as severe headaches, vision changes, and nausea.
Muscle weakness exacerbation in patients with myasthenia gravis.
Clostridium difficile-associated diarrhea due to alteration of normal gut flora.
Arthralgia and joint swelling, particularly in pediatric populations.
Allergic skin reactions including rash, pruritus, and urticaria.
Potential aortic aneurysm and dissection leading to life-threatening bleeding.

Precautions

Avoid use in patients with a history of hypersensitivity to fluoroquinolones.
Use with caution in elderly patients, especially those taking corticosteroids or having renal impairment.
Monitor blood glucose closely in diabetic patients during therapy due to risk of hypoglycemia or hyperglycemia.
Discontinue therapy immediately if signs of tendon inflammation or rupture appear.
Avoid administration in pregnant or breastfeeding women due to potential adverse fetal and neonatal effects.
Monitor for neuropsychiatric symptoms, particularly in patients with known seizure disorders or CNS disease.
Assess renal function prior to dosing and adjust dose accordingly to prevent drug accumulation.
Advise patients to avoid excessive sun exposure and use protective measures against photosensitivity.
Be cautious in patients with known QT prolongation or taking other QT-prolonging drugs.
Avoid use in patients with history of myasthenia gravis due to risk of exacerbating muscle weakness.
Educate patients to report any signs of allergic reactions or severe skin rashes promptly.
Use the full prescribed course to prevent development of resistant organisms.
Avoid concomitant use with products containing multivalent cations without proper timing separation.
Exercise caution when driving or operating machinery until effects on CNS are known.
Regular monitoring of liver function tests is recommended during prolonged therapy.

Warnings

Risk of serious tendon disorders including tendinitis and tendon rupture potentially leading to permanent disability.
Possibility of permanent peripheral neuropathy that can occur at any time during or after treatment.
Severe mood and behavioral changes including agitation, paranoia, hallucinations, memory impairment, and suicidal ideation.
Potential life-threatening hypoglycemia, particularly in diabetic patients treated with antidiabetic agents.
Rare but serious risk of aortic aneurysm and dissection, requiring immediate medical evaluation if chest, stomach, or back pain occurs.
May cause prolongation of the QT interval, predisposing susceptible patients to arrhythmias.
High risk of exacerbation of muscle weakness in myasthenia gravis patients.
Use is associated with Clostridium difficile-associated diarrhea, which can be fatal if not treated promptly.
Possible serious allergic reactions including anaphylaxis and severe dermatologic reactions.
Increased intracranial pressure and convulsions have been reported.
Avoid use in pediatric patients unless absolutely necessary due to potential musculoskeletal adverse effects.
Should not be used for viral infections such as common cold or flu.
Potential false-positive urine drug screening tests result in incorrect clinical interpretation.
Avoid concurrent use with certain drugs that can decrease levofloxacin effectiveness or increase toxicity.
Emergency medical care required if severe and constant chest, stomach, or back pain develops.

Contraindication

Known hypersensitivity to levofloxacin or other fluoroquinolone antibiotics.
History of tendon disorders related to fluoroquinolone administration.
Concurrent use with tizanidine due to risk of hypotension and CNS depression.
Patients with known or suspected to have myasthenia gravis due to risk of exacerbation.
Use during pregnancy and breastfeeding unless no alternative therapy is available.
Patients with history of QT prolongation or those taking other medicines known to prolong QT interval.
Known hypersensitivity to any component of the formulation.
Usage in children and adolescents for routine infections, except where benefits outweigh risks.

Drug Interactions

Antacids containing magnesium or aluminum, sucralfate, iron or zinc supplements reduce levofloxacin absorption; separate dosing by at least 2 hours.
Didanosine powder or chewable tablets decrease levofloxacin bioavailability; dose separation required.
Theophylline plasma levels can be elevated when co-administered, increasing risk of toxicity.
Concurrent use with warfarin may enhance anticoagulant effects necessitating monitoring of INR.
NSAIDs including ibuprofen, naproxen, and others may increase risk of CNS stimulation and seizures.
Oral diabetes medications or insulin may lead to additive effects on blood glucose, requiring close monitoring.
Diuretics can potentiate hypokalemia and increase risk of QT prolongation.
Corticosteroids increase risk of tendon rupture when used concomitantly.
Some antidepressants and antipsychotics can increase risk for QT prolongation when combined.
Drugs prolonging QT interval such as amiodarone or sotalol may have additive cardiotoxic effects.
Concurrent use with CYP1A2 substrates may alter drug clearance though levofloxacin is minimally metabolized.
May interfere with urine drug screening tests leading to false-positive results.
Use with probenecid can reduce renal excretion of levofloxacin, increasing systemic exposure.
Concomitant administration of multivalent cation-containing products requires careful timing adjustments to prevent reduced efficacy.

Preparations Of The Drug

Oral tablet formulations: 250 mg, 500 mg, and 750 mg strengths for flexible dosing.
Oral solution: 25 mg/mL concentration supplied in 60 mL bottles, intended for patients unable to swallow tablets.
Intravenous formulations exist but are outside the scope of oral administration information.
Preparation for oral solution includes using dosing syringes or calibrated measuring devices to ensure accurate dosing.
Storage of tablets and oral solution should be at room temperature, protected from moisture and heat.
Tablets may be administered with or without food; oral solution should be taken on an empty stomach to optimize absorption.
Levofloxacin tablets feature film coating to facilitate swallowing and patient compliance.
Packaging includes child-resistant containers and clear labeling with dosage instructions.
Patient education materials accompany drug to inform about potential side effects and precautions.
Dosing regimens and formulations are optimized for once-daily administration to enhance adherence.